The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 12, 2019
Filed:
May. 03, 2016
Pfizer Inc., New York, NY (US);
Annaliesa Sybil Anderson, Upper Saddle River, NJ (US);
Amardeep Singh Bhupender Bhalla, Montvale, NJ (US);
Robert G. K. Donald, South Orange, NJ (US);
Jianxin Gu, Paramus, NJ (US);
Kathrin Ute Jansen, New York, NY (US);
Rajesh Kumar Kainthan, Tappan, NY (US);
Lakshmi Khandke, Nanuet, NY (US);
Jin-Hwan Kim, Suffern, NY (US);
Paul Liberator, Holmdel, NJ (US);
Avvari Krishna Prasad, Chapel Hill, NC (US);
Mark Edward Ruppen, Garnerville, NY (US);
Ingrid Lea Scully, Cornwall, NY (US);
Suddham Singh, Monroe, NY (US);
Cindy Xudong Yang, Tappan, NY (US);
Pfizer Inc., New York, NY (US);
Abstract
The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from, commonly referred to as group B(GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.